Since CPE complexes are formed in the intestines [8], where intestinal proteases are present, it is possible that CLDN-1-mediated protease resistance helps to protect the CPE large complexes, and thus enhance CPE activity, during intestinal disease. Here, CLDN1 is linked to intestinal disorder.